Immuno-oncology company Affimed to be delisted from Nasdaq after insolvency filing

Written by Emily J. Thompson, Senior Investment Analyst

AFMD%

Source: SeekingAlpha

Updated: May 14 2025

0mins

Source: SeekingAlpha

Affimed N.V. Delisting Notice: Affimed N.V. received a notice from Nasdaq regarding the suspension of its shares effective May 20, 2025, following its filing for insolvency in Germany on May 13, 2025.
Stock Price Decline: The company's stock price fell by 10% to $0.12 during pre-market trading after the announcement of its insolvency proceedings.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Immuno-oncology company Affimed to be delisted from Nasdaq after insolvency filing

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Realty Income (O): Reliable Dividend Stock with 5.4% Yield

Nvidia (NVDA) Launches Vera Rubin Chip Production Six Months Early, Forecasts 155% Sales Growth

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch